Corporate Member EMD Serono - NEW Approval

Corporate Member EMD Serono - NEW Approval

BAVENCIO® (avelumab)
March, 2017

BAVENCIO is a programmed death ligand-1 (PD-L1) blocking antibody indicated for the treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma (MCC).

 
 
Become a NOS Member Today!
 

Platinum Corporate Members

Gold Corporate Members